Allergan eyelash drug wins U.S. panel backing

ROCKVILLE, Maryland (Reuters) - An Allergan Inc glaucoma drug is safe and effective enough for U.S. regulators to approve cosmetic use to lengthen and thicken eyelashes, a U.S. advisory panel unanimously ruled on Friday.

The drug is known generically as bimatoprost and is sold for glaucoma under the name Lumigan. Allergan estimates the eyelash use could fetch more than $500 million in global sales per year.

(Reporting by Susan Heavey; editing by Gerald E. McCormick)


Related Posts:

BOSTON (Reuters) - Allergan Inc, maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse. Latisse is designed to treat a condition known as hypotrichosis of the eyelashes, in which a person has does not have enough eyelashes. The active ingredient in Latisse is bimatroprost, the same ingredient

Full Post: FDA approves Allergan’s drug for longer eyelashes

By Susan Heavey WASHINGTON (Reuters) - Data show Novartis AG’s combination malaria drug Coartem appears to work and causes few serious side effects, U.S. Food and Drug Administration regulatory staff said in documents released on Monday. “The majority of AEs (adverse events) were of mild or moderate intensity. Deaths … and SAEs (serious adverse events) … were

Full Post: Novartis malaria drug safe, effective: FDA

WASHINGTON (Reuters) - U.S. health regulatory staff have questioned whether there are enough data to show that Female Health Co’s latest condom for women prevents pregnancy and sexually transmitted diseases, according to documents released on Tuesday. The Chicago-based company is seeking Food and Drug Administration approval to sell its new version, called the FC2 Female Condom,

Full Post: FDA staff debate data for new female condom

By Susan Heavey WASHINGTON (Reuters) - U.S. health regulators are questioning whether clinical trials proposed by ImClone Systems and Amgen Inc will be adequate to show that patients with a certain type of gene are more likely to be helped by two cancer drugs, according to documents released on Friday. Early research has indicated that patients with

Full Post: FDA questions Lilly, Amgen cancer drug trials

By Susan Heavey NEW YORK (Reuters) - Medicare, the U.S. government’s largest payer of health care, said on Monday it does not plan to cover weight-loss surgery in diabetic patients who are not dangerously overweight, saying there is not enough evidence to show it can improve their health. Medicare and some private insurers already pay for the

Full Post: Medicare wants limits for weight loss surgery

Site Navigation

Most Read